Your browser doesn't support javascript.
loading
Development and Characterization of a Wee1 Kinase Degrader.
Li, Zhengnian; Pinch, Benika J; Olson, Calla M; Donovan, Katherine A; Nowak, Radoslaw P; Mills, Caitlin E; Scott, David A; Doctor, Zainab M; Eleuteri, Nicholas A; Chung, Mirra; Sorger, Peter K; Fischer, Eric S; Gray, Nathanael S.
Afiliación
  • Li Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Pinch BJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA; Department of Chemical Biology, Harvard University, Cambridge, MA, USA.
  • Olson CM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Mills CE; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
  • Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Doctor ZM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological and Biomedical Sciences, Harvard Medical School, Boston, MA, USA.
  • Eleuteri NA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Chung M; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
  • Sorger PK; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
  • Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic address: nathanael_gray@dfci.harvard.edu.
Cell Chem Biol ; 27(1): 57-65.e9, 2020 01 16.
Article en En | MEDLINE | ID: mdl-31735695
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinonas / Talidomida / Proteínas Tirosina Quinasas / Proteínas de Ciclo Celular / Inhibidores de Proteínas Quinasas / Proteolisis / Desarrollo de Medicamentos Límite: Female / Humans Idioma: En Revista: Cell Chem Biol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinonas / Talidomida / Proteínas Tirosina Quinasas / Proteínas de Ciclo Celular / Inhibidores de Proteínas Quinasas / Proteolisis / Desarrollo de Medicamentos Límite: Female / Humans Idioma: En Revista: Cell Chem Biol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos